Therefore, this study intended to explore the clinical efficacy and safety of albumin paclitaxel combined with intrapleural infusion of bevacizumab + lobaplatin for the second-line treatment of patients with driver gene-negative NS-NSCLC with pleural effusion and analyze the factors that affect the prognosis. Here, ALB is linked to Pleural effusion.